Acadia Pharmaceuticals Inc. Has A Problem With Nuplazid
March 06, 2017 at 17:36 PM EST
With over $500 million in cash & equivalents, Acadia Pharmaceuticals has the flexibility to wait and be patient for a deal that makes sense and fully appreciates the commercial potential for Nuplazid
